Chris Nolet

CIK: 0001782814

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

AVBP

ArriVent BioPharma, Inc.

Director

JSPR

Jasper Therapeutics, Inc.

Director

RVNC

Revance Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

AVBP
ArriVent BioPharma, Inc.
Jun 18, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
13.6K shares-
JSPR
Jasper Therapeutics, Inc.
Jul 3, 2025
Award(A)
Stock Option (right to buy)
Direct
7.5K shares-
AVBP
ArriVent BioPharma, Inc.
Jun 18, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
15.5K shares-
RVNC
Revance Therapeutics, Inc.
Feb 6, 2025
Disposition(D)
Direct
15K shares-
RVNC
Revance Therapeutics, Inc.
Feb 4, 2025
Tender Offer(U)
Direct
28.6K shares at avg. $3.65$104K

		Type	Shares	Price		Ownership
Jun 18, 2026	AVBP ArriVent BioPharma, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	13,562	-	-	Direct
Jul 3, 2025	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	7,500	-	-	Direct
Jun 18, 2025	AVBP ArriVent BioPharma, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	15,502	-	-	Direct
Feb 6, 2025	RVNC Revance Therapeutics, Inc.	Disposition(D)	15,000	-	-	Direct
Feb 4, 2025	RVNC Revance Therapeutics, Inc.	Tender Offer(U)	28,606	$3.65	$104,412	Direct

1-5 of 5 transactions

About Nolet Chris

Nolet Chris (SEC CIK 0001782814) files insider reports with the SEC as Director of ArriVent BioPharma, Inc. (AVBP), Director of Jasper Therapeutics, Inc. (JSPR) and Director of Revance Therapeutics, Inc. (RVNC).

Signal8 holds 4 ownership filings by Nolet Chris, all Form 4s, filed between Feb 6, 2025 and Jun 22, 2026. Those filings report 5 transactions, from Feb 4, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Nolet Chris's filings is in NEWTOWN SQUARE, PA.

Recent filings by Nolet Chris

Jun 18, 2026: Grant or award of AVBP derivative securities (Form 4, code A).
Jul 3, 2025: Grant or award of JSPR derivative securities (Form 4, code A).
Jun 18, 2025: Grant or award of AVBP derivative securities (Form 4, code A).
Feb 6, 2025: Disposition to issuer transaction of RVNC shares (Form 4, code D).
Feb 4, 2025: Tender of shares transaction of RVNC shares (Form 4, code U).

Other insiders filing for ArriVent BioPharma, Inc. (AVBP)

LaChapelle Robin, Chief Operating Officer
Parsey Merdad, Director
Peterson Kristine, Director
Hohneker John, Director
Lutzker Stuart, President of R&D
Kung Winston, Chief Financial Officer

How to read Form 4 transaction codes